TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15460213

Group type: EXPERIMENTAL
Intervention: Standardized European mistletoe extract (Viscum album L., Iscador) given in addition to conventional adjuvant oncologic therapy for at least three months.
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Conventional therapy only (control group).
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Standardized European mistletoe extract (Viscum album L., Iscador) given in addition to conventional adjuvant oncologic therapy.
Number of subjects: 1442
Study: 11585017

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (OCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9613295

Group type: EXPERIMENTAL
Intervention: Propofol (1, 2, 3, 4, 5 or 6 micrograms.ml‐1) and Sufentanil (0.1, 0.2, 0.3, 0.5 or 1.0 ng.ml‐1) target concentrations for induction of anaesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Median frequency
Number of subjects: 30
Study: 7924126

Group type: EXPERIMENTAL
Intervention: Isoproterenol with normoxia-normocapnia gas mixture
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Isoproterenol with hypercapnia gas mixture
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Isoproterenol with hypoxemia-hypercapnia gas mixture
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypercapnia (end-tidal PaCO2, 50 mm Hg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypoxemia-hypercapnia (arterial oxygen saturation, 90%; PaCO2, 50 mm Hg)
Number of subjects: 9
Study: 31651206

Group type: EXPERIMENTAL
Intervention: C2Hear reusable learning objects (RLOs)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Printed booklet on hearing aids (Control)
Number of subjects: 56
Study: 31004126

Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (tPBM) using NIR light (810 nm, pulsed at 40 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 27858673

Group type: COMPARATOR
Intervention: Single suprascapular nerve block (SSNB)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Multiple (nine) suprascapular nerve blocks (SSNB)
Number of subjects: 96
Study: 26939326

Group type: EXPERIMENTAL
Intervention: Encircling needling combined with physical factor therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional nursing, ultrasonic wave and short-wave ultraviolet therapy (Control group)
Number of subjects: 34
Study: 23973694

Group type: COMPARATOR
Intervention: Circumferential PVI
Number of subjects: 242

Group type: COMPARATOR
Intervention: Anatomic ablation of the main left atrial GP
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Circumferential PVI followed by anatomic ablation of the main left atrial GP
Number of subjects: 242
Study: 20570416

Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold In-Tube test (QFG-IT)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Tuberculin test
Number of subjects: 118
Study: 17763228

Group type: EXPERIMENTAL
Intervention: SpeediCath Compact catheter
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard-length female catheter
Number of subjects: 24
Study: 15870042

Group type: EXPERIMENTAL
Intervention: PRECiSe
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard heart-lung machine (Control)
Number of subjects: 40
Study: 12065173

Group type: EXPERIMENTAL
Intervention: EV+LNG (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TSE2+TSLNG (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (Group B)
Number of subjects: 30
Study: 10361566

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (up to 12 sessions)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 400
Study: 8542914

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg administered by an auto‐injector
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual acute migraine treatments
Number of subjects: 246
Study: 2361567

Group type: EXPERIMENTAL
Intervention: 20 mg frusemide/2.5 mg amiloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 mg frusemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 531993

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) three times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dipyridamole (75 mg) three times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) plus Dipyridamole (75 mg) three times daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31867908

Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen needling treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional medicines and conventional needling treatment
Number of subjects: 64
Study: 28710202

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) combined with Traditional Programme (TP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional Programme (TP)
Number of subjects: 120
Study: 26085631

Group type: EXPERIMENTAL
Intervention: Visual detection responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prestimulus activity in the prefrontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prestimulus activity in the default-mode network
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poststimulus connectivity between prefrontal cortex and visual system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dorsal visual stream activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prestimulus activity in the auditory cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poststimulus neural coupling between auditory and sensorimotor cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Connectivity with the default-mode network
Number of subjects: 0
Study: 23689595

Group type: EXPERIMENTAL
Intervention: 100 mg vitamin C/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 180 mg vitamin C/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vitamin C (unspecified dose)
Number of subjects: 33
Study: 21349889

Group type: EXPERIMENTAL
Intervention: Cranial osteopathy (six sessions with a registered osteopath)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (waiting list with partial attention control)
Number of subjects: 142
Study: 19427810

Group type: EXPERIMENTAL
Intervention: Manual massage and mobilization of the feet and ankles
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17716335

Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2)/day (group A, n = 34)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (group B, n = 23)
Number of subjects: 75
Study: 15100514

Group type: EXPERIMENTAL
Intervention: Tc methylene diphosphonate (Tc‐MDP) bone scan
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tc hexamethylproplyene amine oxime (Tc‐HMPAO) labelled white blood cell (WBC) scan
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tc microcolloid bone marrow (BM) scan
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combination of WBC scan and BM scan
Number of subjects: 77
Study: 12714834

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravenous heparin with aspirin
Number of subjects: 52
Study: 9839101

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5‐5 mg twice a day)
Number of subjects: 883

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5‐25 mg twice a day)
Number of subjects: 883
Study: 7916399

Group type: EXPERIMENTAL
Intervention: Routine cervical examinations at every prenatal visit (experimental group)
Number of subjects: 5602

Group type: COMPARATOR
Intervention: Avoidance of cervical examination if possible (control group)
Number of subjects: 5602
Study: 2815969

Group type: EXPERIMENTAL
Intervention: Inactivated whole‐virion trivalent influenza vaccine (A/Leningrad/360/86(H3N2), A/Taiwan/5/87 and B/Ann Arbor/1/86)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (young adults)
Number of subjects: 72
Study: 1173059

Group type: EXPERIMENTAL
Intervention: 10 mg of intravenous propranolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 mg of intravenous tolamolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg of intravenous tolamolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 15
Study: 30684589

Group type: EXPERIMENTAL
Intervention: Achievement stress
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Social rejection stress
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 168
Study: 27502307

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study: 26358285

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16492

Group type: EXPERIMENTAL
Intervention: Longer diabetes duration
Number of subjects: 16492
Study: 24687538

Group type: EXPERIMENTAL
Intervention: Automated IT-based telephone monitoring system for symptom reporting
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (attentional control)
Number of subjects: 250
Study: 22113257

Group type: EXPERIMENTAL
Intervention: Telephone-based exercise intervention (10 phone calls over 16 weeks)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Telephone-based exercise intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 121
Study: 20007011

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (10mg b.i.d.)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 146
Study: 18075905

Group type: EXPERIMENTAL
Intervention: TFJ stabilized
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TFJ not stabilized
Number of subjects: 20
Study: 16315242

Group type: EXPERIMENTAL
Intervention: Regimen A (carboplatin/etoposide)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Regimen B (ifosfamide/etoposide)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Regimen C (cyclophosphamide/etoposide)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Overall Survival (OS)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Event-Free Survival (EFS)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Time to an event
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Response to HDCT
Number of subjects: 76
Study: 12096385

Group type: EXPERIMENTAL
Intervention: Transmission of digitized clinical records supported by access to video and data conferencing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9458199

Group type: EXPERIMENTAL
Intervention: Amiprilose hydrochloride
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 7636658

Group type: EXPERIMENTAL
Intervention: rHuEPO 300 units/kg per week
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: rHuEPO 750 units/kg per week
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 97
Study: 2750683

Group type: EXPERIMENTAL
Intervention: Antimicrobial regimens that suppressed menaquinone‐producing intestinal microflora and contained an N‐methylthiotetrazole (NMTT) moiety
Number of subjects: 34

Group type: COMPARATOR
Intervention: Antimicrobial agents that preserved the microflora and contained no NMTT moiety
Number of subjects: 34
Study: 352631

Group type: EXPERIMENTAL
Intervention: Halcinonide-neomycin-amphotericin ointment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrocortisone ointment
Number of subjects: 50
Study: 31724191

Group type: EXPERIMENTAL
Intervention: BCD-020
Number of subjects: 174

Group type: COMPARATOR
Intervention: Comparator (reference rituximab)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Both BCD-020 and Comparator
Number of subjects: 174
Study: 29739385

Group type: EXPERIMENTAL
Intervention: Augmented physical education program (270 minutes of weekly physical education)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Augmented physical education program
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Physical activity outcomes
Number of subjects: 312
Study: 29931852

Group type: EXPERIMENTAL
Intervention: DEX (1 μg/kg before induction and 0.5 μg/(kg·h) maintenance)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 54
Study: 24867834

Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A injection
Number of subjects: 0
Study: 22659759

Group type: EXPERIMENTAL
Intervention: Topical 5% ketamine cream
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 17
Study: 20113941

Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 58
Study: 18617707

Group type: EXPERIMENTAL
Intervention: Telehomecare
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study: 16092677

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (10 ml)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 115
Study: 12117400

Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 35000
Study: 10598014

Group type: EXPERIMENTAL
Intervention: Fentanyl-propofol (propofol group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam-ketamine (M-K group, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8607392

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 239

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 239
Study: 2021542

Group type: EXPERIMENTAL
Intervention: MOPP (mustine, Oncovin, procarbazine, prednisone)
Number of subjects: 290

Group type: COMPARATOR
Intervention: LOPP (Leukeran substituted for mustine)
Number of subjects: 290

Group type: COMPARATOR
Intervention: LOPP
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 290
Study: 7081979

Group type: EXPERIMENTAL
Intervention: Cephalosporin-aminoglycoside combinations (cephalothin and tobramycin; cephalothin and gentamicin; cefamandole and tobramycin; cefamandole and gentamicin)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Children (cephalosporin-aminoglycoside combinations)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Adults (cephalosporin-aminoglycoside combinations)
Number of subjects: 199
Study: 31482193

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation
Number of subjects: 426824

Group type: EXPERIMENTAL
Intervention: Genetic liability to alcohol dependence
Number of subjects: 426824

Group type: COMPARATOR
Intervention: Genetically predicted alcohol and coffee intake
Number of subjects: 426824
Study: 29053118

Group type: EXPERIMENTAL
Intervention: Nooklerin (deanoli aceglumas) administered as add-on treatment at a daily dose of 1000 mg for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group receiving standard psychopharmacological treatment without nooklerin
Number of subjects: 60
Study: 25677355

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 110

Group type: COMPARATOR
Intervention: Relaxation Therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: IPT
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: IPT and Prolonged Exposure
Number of subjects: 110
Study: 23937405

Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop (AP), active application (APA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Adper Prompt L‐Pop (AP), passive application (APP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Xeno III (XE), active application (XEA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Xeno III (XE), passive application (XEP)
Number of subjects: 31
Study: 22935960

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 1,200 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18952228

Group type: EXPERIMENTAL
Intervention: Vitamin C (450 mg/d in 3 doses for 6 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (5% dextrose, identical administration)
Number of subjects: 20
Study: 17615450

Group type: EXPERIMENTAL
Intervention: Education program for safe drug use (1.5 hours, once a week for 3 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no education program)
Number of subjects: 40
Study: 15097245

Group type: EXPERIMENTAL
Intervention: telmisartan 20 mg
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 1039

Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 1039

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1039
Study: 11579944

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg twice weekly for 12 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bromocriptine (2.5 mg or 5 mg twice daily for 12 weeks)
Number of subjects: 17
Study: 9538967

Group type: EXPERIMENTAL
Intervention: Lispro
Number of subjects: 23
Study: 7854921

Group type: COMPARATOR
Intervention: Discriminant analysis using parameters from 99mTc‐MAG3 renogram (mean transit time, time at 20% of initial height, time to peak).
Number of subjects: 82
Study: 3122919

Group type: EXPERIMENTAL
Intervention: Relaxation therapy conducted by general practitioners in group sessions once a week for eight weeks, accompanied by galvanic skin resistance biofeedback.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no relaxation therapy).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation therapy conducted by general practitioners.
Number of subjects: 0
Study: 30516328

Group type: EXPERIMENTAL
Intervention: Rapid induction chemotherapy (COJEC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard 3-weekly chemotherapy
Number of subjects: 69
Study: 28351880

Group type: EXPERIMENTAL
Intervention: School-based play intervention
Number of subjects: 1752
Study: 26154816

Group type: EXPERIMENTAL
Intervention: B-Complex (n=21)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Broad-spectrum mineral/vitamin formula (BSMV, n=18)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Single nutrient (vitamin D, n=17)
Number of subjects: 56
Study: 23632233

Group type: EXPERIMENTAL
Intervention: BMI 30.0-34.9
Number of subjects: 86000

Group type: EXPERIMENTAL
Intervention: BMI 35.0-39.9
Number of subjects: 86000

Group type: EXPERIMENTAL
Intervention: BMI 40.0+
Number of subjects: 86000

Group type: COMPARATOR
Intervention: Normal BMI (18.5-24.9)
Number of subjects: 86000
Study: 17148625

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 14669815

Group type: EXPERIMENTAL
Intervention: Master Amino Acid Pattern (MAP®) as a dietary protein substitute
Number of subjects: 0
Study: 10437621

Group type: EXPERIMENTAL
Intervention: Endoscopic repair (TAPP and TEP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional suture technique and tension-free surgery
Number of subjects: 41
Study: 8553384

Group type: EXPERIMENTAL
Intervention: Power-based transcranial color-coded duplex sonography (p-TCCD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Frequency-based transcranial color-coded duplex sonography (f-TCCD)
Number of subjects: 30
Study: 2060540

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg t.i.d. for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg t.i.d. for 4 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6344551

Group type: EXPERIMENTAL
Intervention: Urabe Am 9-Schwarz
Number of subjects: 193

Group type: COMPARATOR
Intervention: Jeryl Lynn-Moraten
Number of subjects: 193
Study: 31028610

Group type: EXPERIMENTAL
Intervention: High-dose epirubicin 150 mg/m2 and cyclophosphamide 1500 mg/m2 with filgrastim support every 3 weeks for 3 cycles (HDEC)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard dose epirubicin 75 mg/m2 and cyclophosphamide 750 mg/m2 every 3 weeks for 6 cycles (SDEC)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: HDEC
Number of subjects: 235

Group type: COMPARATOR
Intervention: SDEC
Number of subjects: 235
Study: 29089403

Group type: EXPERIMENTAL
Intervention: STAR intervention for childhood obesity
Number of subjects: 2000000
Study: 26075488

Group type: EXPERIMENTAL
Intervention: d‐MPH (0.15 mg/kg) with ethanol (0.6 g/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: dl‐MPH (0.3 mg/kg) with ethanol (0.6 g/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: d‐MPH (0.15 mg/kg)
Number of subjects: 24
Study: 23876323

Group type: EXPERIMENTAL
Intervention: Caffeine administration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 24
Study: 21481230

Group type: EXPERIMENTAL
Intervention: Neuromuscular training programme with injury prevention counselling
Number of subjects: 968

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 968
Study: 19383110

Group type: EXPERIMENTAL
Intervention: Asthma Control Test (ACT) score
Number of subjects: 383

Group type: COMPARATOR
Intervention: Spirometry, PEFR, FeNO, BHR
Number of subjects: 383
Study: 16772451

Group type: COMPARATOR
Intervention: EPO [2100 U EPO/(kg.wk)]
Number of subjects: 3

Group type: COMPARATOR
Intervention: IV Fe+EPO [2 mg IV sucrose Fe/(kg.d) plus 2100 U EPO/(kg.wk)]
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 15588324

Group type: EXPERIMENTAL
Intervention: Information programme and website
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Decision analysis
Number of subjects: 660

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 660
Study: 12439369

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0